.png){kind=icon}
.png){kind=icon}
Return
Dupilumab for patients with allergic fungal rhinosinusitis
.png){kind=icon}
OA
AI
A
J
S
J
M
L
R
P
P
J
G
A
N
L
DOI：10.1016/j.jaci.2026.07.006.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Allergic fungal rhinosinusitis (AFRS) is a severe subtype of chronic rhinosinusitis characterized by fungal hypersensitivity and accentuated type 2 inflammation. Dupilumab—a fully human monoclonal antibody blocking interleukin-4/13, approved for type 2 inflammatory diseases, including chronic rhinosinusitis with nasal polyps—may benefit patients with AFRS.
Keywords:
Allergic fungal rhinosinusitis
asthma
dupilumab
quality of life
surgery
systemic corticosteroids
type 2 inflammation
3D
3-dimensional
ACQ-6
asthma control questionnaire 6-item version
AFRS
allergic fungal rhinosinusitis
COVID-19
coronavirus disease
CRS
chronic rhinosinusitis
CRSwNP
chronic rhinosinusitis with nasal polyps
CT
computed tomography
FEV1
forced expiratory volume in 1 second
IgE
immunoglobulin E
IL
interleukin
LMK
Lund−Mackay
LoS
loss of smell
LSMD
least squares mean difference
NCS
nasal congestion score
NPS
nasal polyp score
q2w
every 2 weeks
q4w
every 4 weeks
SAE
serious adverse event
SCS
systemic corticosteroids
SD
standard deviation
SNOT-22
22-item Sino-Nasal Outcome Test
TEAE
treatment-emergent adverse event
TSS
total symptom score
UPSIT
University of Pennsylvania Smell Identification Test
Journal
IF:
11.2
Papers:
3.7W
Citations:
5.6W
Organization
Cited Papers